HER2 breast cancer therapies: a review

Conleth G Murphy, Shanu ModiBreast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USAAbstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Conleth G Murphy, Shanu Modi
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://doaj.org/article/3a73e9c2eef24772a3f1de13accb894c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:3a73e9c2eef24772a3f1de13accb894c
record_format dspace
spelling oai:doaj.org-article:3a73e9c2eef24772a3f1de13accb894c2021-12-02T05:50:50ZHER2 breast cancer therapies: a review1177-54751177-5491https://doaj.org/article/3a73e9c2eef24772a3f1de13accb894c2009-06-01T00:00:00Zhttp://www.dovepress.com/her2-breast-cancer-therapies-a-review-a3250https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Conleth G Murphy, Shanu ModiBreast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USAAbstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been shown to be associated with poorer outcomes compared to ‘HER2 normal’ breast cancer. Research has focused on developing therapies directed to the HER2 receptor and its pathway. These include the monoclonal antibody trastuzumab, which has improved outcomes when used in patients with both advanced and early breast cancer. Lapatinib is a small-molecule tyrosine kinase inhibitor which has demonstrated activity in advanced breast cancer and is currently being evaluated in early stage disease. We discuss the therapeutic rationale and clinical trial experience with these agents. Other novel and emerging strategies targeting the HER2 receptor and its pathway are also discussed. These strategies include novel HER2 antibodies and small-molecule inhibitors, antibody–drug conjugates, agents targeting downstream components of the HER2 signaling pathway, and heat shock protein 90 (HSP90) inhibitors.Keywords: HER2, human epidermal growth factor receptor 2, breast cancer, trastuzumab, lapatinib Conleth G MurphyShanu ModiDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 289-301 (2009)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Conleth G Murphy
Shanu Modi
HER2 breast cancer therapies: a review
description Conleth G Murphy, Shanu ModiBreast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USAAbstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been shown to be associated with poorer outcomes compared to ‘HER2 normal’ breast cancer. Research has focused on developing therapies directed to the HER2 receptor and its pathway. These include the monoclonal antibody trastuzumab, which has improved outcomes when used in patients with both advanced and early breast cancer. Lapatinib is a small-molecule tyrosine kinase inhibitor which has demonstrated activity in advanced breast cancer and is currently being evaluated in early stage disease. We discuss the therapeutic rationale and clinical trial experience with these agents. Other novel and emerging strategies targeting the HER2 receptor and its pathway are also discussed. These strategies include novel HER2 antibodies and small-molecule inhibitors, antibody–drug conjugates, agents targeting downstream components of the HER2 signaling pathway, and heat shock protein 90 (HSP90) inhibitors.Keywords: HER2, human epidermal growth factor receptor 2, breast cancer, trastuzumab, lapatinib
format article
author Conleth G Murphy
Shanu Modi
author_facet Conleth G Murphy
Shanu Modi
author_sort Conleth G Murphy
title HER2 breast cancer therapies: a review
title_short HER2 breast cancer therapies: a review
title_full HER2 breast cancer therapies: a review
title_fullStr HER2 breast cancer therapies: a review
title_full_unstemmed HER2 breast cancer therapies: a review
title_sort her2 breast cancer therapies: a review
publisher Dove Medical Press
publishDate 2009
url https://doaj.org/article/3a73e9c2eef24772a3f1de13accb894c
work_keys_str_mv AT conlethgmurphy her2breastcancertherapiesareview
AT shanumodi her2breastcancertherapiesareview
_version_ 1718400166135857152